Institutional Investors Are Betting On Array Biopharma Inc (NASDAQ:ARRY)

May 20, 2018 - By Ellis Scott

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Sentiment for Array Biopharma Inc (NASDAQ:ARRY)

Array Biopharma Inc (NASDAQ:ARRY) institutional sentiment increased to 1.3 in 2017 Q4. Its up 0.09, from 1.21 in 2017Q3. The ratio is better, as 91 investment professionals opened new or increased positions, while 70 decreased and sold equity positions in Array Biopharma Inc. The investment professionals in our partner’s database now possess: 194.11 million shares, up from 190.80 million shares in 2017Q3. Also, the number of investment professionals holding Array Biopharma Inc in their top 10 positions increased from 4 to 6 for an increase of 2. Sold All: 20 Reduced: 50 Increased: 64 New Position: 27.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $3.27 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

It closed at $15.75 lastly. It is down 68.58% since May 20, 2017 and is uptrending. It has outperformed by 57.03% the S&P500.

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on August, 8. They expect $-0.25 earnings per share, down 47.06 % or $0.08 from last year’s $-0.17 per share. After $-0.11 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 127.27 % negative EPS growth.

Bvf Inc Il holds 13.4% of its portfolio in Array BioPharma Inc. for 8.69 million shares. Redmile Group Llc owns 19.11 million shares or 10.67% of their US portfolio. Moreover, First Light Asset Management Llc has 5.5% invested in the company for 1.57 million shares. The California-based Venbio Select Advisor Llc has invested 4.54% in the stock. Ecor1 Capital Llc, a California-based fund reported 2.88 million shares.

Since January 1, 0001, it had 0 insider buys, and 9 insider sales for $16.27 million activity.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Ratings analysis reveals 100% of Array Biopharma’s analysts are positive. Out of 5 Wall Street analysts rating Array Biopharma, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $17.0 while the high is $23.0. The stock’s average target of $20.60 is 30.79% above today’s ($15.75) share price. ARRY was included in 10 notes of analysts from November 29, 2017. As per Tuesday, February 6, the company rating was maintained by Piper Jaffray. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, February 6. The firm has “Buy” rating given on Wednesday, February 7 by Cowen & Co. The firm earned “Buy” rating on Wednesday, November 29 by Piper Jaffray. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, February 7 report. Cowen & Co maintained the shares of ARRY in report on Thursday, May 10 with “Buy” rating. The firm has “Buy” rating given on Tuesday, February 6 by SunTrust. Cowen & Co maintained it with “Buy” rating and $17.0 target in Sunday, January 21 report. As per Monday, January 22, the company rating was upgraded by Leerink Swann. Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) on Sunday, January 21 with “Buy” rating.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Profitconfidential.com, which released: “ARRY Stock Is Now Primed for a Move Toward Higher Prices” on May 14, 2018. Streetinsider.com‘s article titled: “Array Biopharma (ARRY) Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination …” and published on May 16, 2018 is yet another important article.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.